Health
Mirati to contribute $4 million grant to support SU2C research on KRAS mutant cancers – News-Medical.Net
Stand Up To Cancer and Mirati Therapeutics Inc. – a late-stage targeted oncology company – today announced that Mirati will contribute a $4 million grant to SU2C…
Stand Up To Cancer® (SU2C) and Mirati Therapeutics Inc. – a late-stage targeted oncology company – today announced that Mirati will contribute a $4 million grant to SU2C to develop new approaches to treat patients with KRAS mutant cancers, as a part of the SU2C Catalyst® program.
The research will focus on cancer types with unmet medical needs, and the application of tumor-agnostic strategies and molecular testing to address those needs. Certain cancers can sometimes have mutations in the KRAS gene,…
-
Noosa News17 hours agoBusiness expo sparks inspiration and connection
-
Noosa News17 hours agoSee inside the hidden suburbs where Queensland investors really live
-
Noosa News16 hours agoThe best new books released in August, from Toni Jordan, Rhett Davis and more
-
Business15 hours agoWhy it’s time to buy Domino’s, Flight Centre, and WiseTech shares